<DOC>
	<DOCNO>NCT00782613</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy topical ALT-2074 apply twice daily 28 day treatment chronic plaque psoriasis adult subject . The secondary objective evaluate safety topical ALT-2074 apply twice daily 28 day treatment chronic plaque psoriasis adult subject . Tertiary objective provide visual documentation improvement psoriatic plaque treat ALT-2074 use digital photography , determine extent systemic absorption topically apply ALT-2074 base pharmacokinetic measurement blood concentration .</brief_summary>
	<brief_title>Efficacy Safety Topical ALT-2074 ( SYI-2074 ) Treatment Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects must meet follow criterion qualify entry study : 1 . Men woman 18 75 year old , inclusive . 2 . Clinical diagnosis stable , chronic plaque psoriasis least 6 month prior Visit 1 . 3 . In otherwise good general health free disease physical condition might impair evaluation plaque psoriasis . 4 . Plaque psoriasis treatable area &lt; 10 % BSA . ( Subject palm size equivalent 1 % BSA . ) 5 . Have 2 wellmatched plaque ( target plaque ) approximately 3 8 cm 3 8 cm size area right leave front back , sit knee , knee , elbow , head , face , scalp , palm , intertriginous area . 6 . A Combined Psoriasis Severity Score ( CPSS ) &gt; 6 target plaque Visit 1 . 7 . Willing avoid prolonged exposure treatment area ultraviolet radiation ( natural artificial ) duration study . 8 . Able understand willing comply study requirement , particularly regimen administration study drug . 9 . Able understand willing sign Informed Consent Form . Any subject meet follow criterion qualify entry study : 1 . Women pregnant , lactating , plan become pregnant , woman childbearing potential successfully use medically acceptable contraceptive method previous 3 month , eg , oral contraceptive agent , intrauterine device ( IUD ) , barrier method plus spermicide . 2 . Clinical diagnosis guttate , pustular , erythrodermic , nonplaque form psoriasis . 3 . Use emollient moisturizers area treat within 24 hour prior Visits 1 2 . 4 . Use topical antipsoriatic therapy ( include topical retinoids , corticosteroid , vitamin D analog ) area treat within 2 week prior Visit 2 . 5 . Received systemic immunomodulatory therapy treat psoriasis ( eg , methotrexate , cyclosporine , alefacept , etanercept , infliximab , efalizumab , adalimumab ) within 12 week prior Visit 2 . 6 . Received phototherapy ( include laser ) , photochemotherapy , systemic psoriasis therapy ( eg , systemic corticosteroid , retinoids acitretin ) within 4 week prior Visit 2 . 7 . Recent history ( within past 12 month ) alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 4 oz wine , 1.5 oz distil spirit ) . 8 . History noncompliance medical regimen unwilling comply study protocol . 9 . Participation investigational drug study within 30 day prior Visit 2 . 10 . Serious unstable medical psychological condition opinion Investigator would compromise subject 's safety successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>The primary objective study evaluate</keyword>
	<keyword>efficacy topical ALT-2074 apply twice daily 28</keyword>
	<keyword>day treatment chronic plaque psoriasis adult</keyword>
	<keyword>subject .</keyword>
	<keyword>The secondary objective evaluate safety</keyword>
	<keyword>topical ALT-2074 apply twice daily 28 day</keyword>
	<keyword>treatment chronic plaque psoriasis adult subject .</keyword>
	<keyword>Tertiary objective provide visual documentation</keyword>
	<keyword>improvement psoriatic plaque treat</keyword>
	<keyword>ALT-2074 use digital photography , determine</keyword>
	<keyword>extent systemic absorption topically apply ALT-2074</keyword>
	<keyword>base pharmacokinetic measurement blood</keyword>
	<keyword>concentration .</keyword>
</DOC>